Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16782729rdf:typepubmed:Citationlld:pubmed
pubmed-article:16782729lifeskim:mentionsumls-concept:C1336117lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C1300072lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C0334094lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C1521733lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C0872169lld:lifeskim
pubmed-article:16782729lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:16782729pubmed:issue7lld:pubmed
pubmed-article:16782729pubmed:dateCreated2006-8-4lld:pubmed
pubmed-article:16782729pubmed:abstractTextTo predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas.lld:pubmed
pubmed-article:16782729pubmed:languageenglld:pubmed
pubmed-article:16782729pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:citationSubsetIMlld:pubmed
pubmed-article:16782729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16782729pubmed:statusMEDLINElld:pubmed
pubmed-article:16782729pubmed:monthJullld:pubmed
pubmed-article:16782729pubmed:issn0368-2811lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:WatanabeKen-i...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:NomoriHiroaki...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:NarukeTsuguoTlld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:YamazakiKazut...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:GoyaTomoyukiTlld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:KobayashiTosh...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:OrikasaHideki...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:UnoKimiichiKlld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:OhtsukaTakash...lld:pubmed
pubmed-article:16782729pubmed:authorpubmed-author:EbiharaAkinor...lld:pubmed
pubmed-article:16782729pubmed:issnTypePrintlld:pubmed
pubmed-article:16782729pubmed:volume36lld:pubmed
pubmed-article:16782729pubmed:ownerNLMlld:pubmed
pubmed-article:16782729pubmed:authorsCompleteYlld:pubmed
pubmed-article:16782729pubmed:pagination403-9lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:meshHeadingpubmed-meshheading:16782729...lld:pubmed
pubmed-article:16782729pubmed:year2006lld:pubmed
pubmed-article:16782729pubmed:articleTitle[F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.lld:pubmed
pubmed-article:16782729pubmed:affiliationDepartment of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan.lld:pubmed
pubmed-article:16782729pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16782729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16782729lld:pubmed